Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case report
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | por |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/47750 |
Resumo: | Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. |
| id |
CRUZ_42e4f6a35c25368dec2a0efdc456c809 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/47750 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Senegaglia, Alexandra CristinaRebelatto, Carmen Lúcia KuniyoshiFranck, Claudio LucianoLima, Juliana SouzaBoldrini-Leite, Lidiane MariaDaga, Debora ReginaLeitão, Cleverson AlexShigunov, PatríciaAzambuja, Ana Paula deBana, ElisaMarsaro, Daniela BoscaroSchaidt, BrunaMicosky, AndressaJamur, Valderez RavaglioSchluga, YaraVaz, Isadora MayRibeiro, Lisandro LimaCorrea, AlejandroBrofman, Paulo Roberto Slud2021-06-17T17:21:54Z2021-06-17T17:21:54Z2021SENEGAGLIA, Alexandra Cristina et al. Combined use of Tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case Report. Cell Transplantation, v. 30, p. 1–10, 2021.1555-3892https://www.arca.fiocruz.br/handle/icict/4775010.1177/09636897211021008porSAGE PublicationsTocilizumabeMesenchymal Stem CellsUmbilical CordAntibodies, MonoclonalCélulas Madre MesenquimatosasCordón UmbilicalAnticuerpos MonoclonalesCellules souches mésenchymateusesCordon ombilicalAnticorps monoclonauxCOVID-19Células-Tronco MesenquimaisCordão UmbilicalAnticorpos MonoclonaisSARS-CoV-2Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case reportinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlePontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Hospital Nossa Senhora do Pilar. Curitiba, PR, Brasil.Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Básica de Células Tronco. Curitiba, PR, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Hospital Nossa Senhora do Pilar. Curitiba, PR, Brasil.Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil.Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil.Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil.Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.Hospital Nossa Senhora do Pilar. Curitiba, PR, Brasil.Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Básica de Células Tronco. Curitiba, PR, Brasil.Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil.The coronavirus pandemic is one of the most significant public health events in recent history. Currently, no specific treatment is available. Some drugs and cell-based therapy have been tested as alternatives to decrease the disease’s symptoms, length of hospital stay, and mortality. We reported the case of a patient with a severe manifestation of COVID-19 in critical condition who did not respond to the standard procedures used, including six liters of O2 supplementation under a nasal catheter and treatment with dexamethasone and enoxaparin in prophylactic dose. The patient was treated with tocilizumab and an advanced therapy product based on umbilical cord-derived mesenchymal stromal cells (UC-MSC). The combination of tocilizumab and UC-MSC proved to be safe, with no adverse effects, and the results of this case report prove to be a promising alternative in the treatment of patients with severe acute respiratory syndrome due to SARS-CoV-2.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83084https://www.arca.fiocruz.br/bitstream/icict/47750/1/license.txt783568c2893d2e25a99990b126be1772MD51ORIGINAL09636897211021008ok.pdf09636897211021008ok.pdfapplication/pdf1849770https://www.arca.fiocruz.br/bitstream/icict/47750/2/09636897211021008ok.pdf5fa4f533aef0f0f2f1c54c4d55bf4a70MD52TEXT09636897211021008ok.pdf.txt09636897211021008ok.pdf.txtExtracted texttext/plain29768https://www.arca.fiocruz.br/bitstream/icict/47750/3/09636897211021008ok.pdf.txt7a4983e7ec443c846b4c1d91c7ee87ceMD53icict/477502021-06-18 02:01:08.19oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-06-18T05:01:08Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case report |
| title |
Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case report |
| spellingShingle |
Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case report Senegaglia, Alexandra Cristina Tocilizumabe Mesenchymal Stem Cells Umbilical Cord Antibodies, Monoclonal Células Madre Mesenquimatosas Cordón Umbilical Anticuerpos Monoclonales Cellules souches mésenchymateuses Cordon ombilical Anticorps monoclonaux COVID-19 Células-Tronco Mesenquimais Cordão Umbilical Anticorpos Monoclonais SARS-CoV-2 |
| title_short |
Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case report |
| title_full |
Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case report |
| title_fullStr |
Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case report |
| title_full_unstemmed |
Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case report |
| title_sort |
Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case report |
| author |
Senegaglia, Alexandra Cristina |
| author_facet |
Senegaglia, Alexandra Cristina Rebelatto, Carmen Lúcia Kuniyoshi Franck, Claudio Luciano Lima, Juliana Souza Boldrini-Leite, Lidiane Maria Daga, Debora Regina Leitão, Cleverson Alex Shigunov, Patrícia Azambuja, Ana Paula de Bana, Elisa Marsaro, Daniela Boscaro Schaidt, Bruna Micosky, Andressa Jamur, Valderez Ravaglio Schluga, Yara Vaz, Isadora May Ribeiro, Lisandro Lima Correa, Alejandro Brofman, Paulo Roberto Slud |
| author_role |
author |
| author2 |
Rebelatto, Carmen Lúcia Kuniyoshi Franck, Claudio Luciano Lima, Juliana Souza Boldrini-Leite, Lidiane Maria Daga, Debora Regina Leitão, Cleverson Alex Shigunov, Patrícia Azambuja, Ana Paula de Bana, Elisa Marsaro, Daniela Boscaro Schaidt, Bruna Micosky, Andressa Jamur, Valderez Ravaglio Schluga, Yara Vaz, Isadora May Ribeiro, Lisandro Lima Correa, Alejandro Brofman, Paulo Roberto Slud |
| author2_role |
author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Senegaglia, Alexandra Cristina Rebelatto, Carmen Lúcia Kuniyoshi Franck, Claudio Luciano Lima, Juliana Souza Boldrini-Leite, Lidiane Maria Daga, Debora Regina Leitão, Cleverson Alex Shigunov, Patrícia Azambuja, Ana Paula de Bana, Elisa Marsaro, Daniela Boscaro Schaidt, Bruna Micosky, Andressa Jamur, Valderez Ravaglio Schluga, Yara Vaz, Isadora May Ribeiro, Lisandro Lima Correa, Alejandro Brofman, Paulo Roberto Slud |
| dc.subject.other.pt_BR.fl_str_mv |
Tocilizumabe |
| topic |
Tocilizumabe Mesenchymal Stem Cells Umbilical Cord Antibodies, Monoclonal Células Madre Mesenquimatosas Cordón Umbilical Anticuerpos Monoclonales Cellules souches mésenchymateuses Cordon ombilical Anticorps monoclonaux COVID-19 Células-Tronco Mesenquimais Cordão Umbilical Anticorpos Monoclonais SARS-CoV-2 |
| dc.subject.en.pt_BR.fl_str_mv |
Mesenchymal Stem Cells Umbilical Cord Antibodies, Monoclonal |
| dc.subject.es.pt_BR.fl_str_mv |
Células Madre Mesenquimatosas Cordón Umbilical Anticuerpos Monoclonales |
| dc.subject.fr.pt_BR.fl_str_mv |
Cellules souches mésenchymateuses Cordon ombilical Anticorps monoclonaux |
| dc.subject.decs.pt_BR.fl_str_mv |
COVID-19 Células-Tronco Mesenquimais Cordão Umbilical Anticorpos Monoclonais SARS-CoV-2 |
| description |
Pontifícia Universidade Católica do Paraná. Faculdade de Medicina. Núcleo de Tecnologia Celular. Curitiba, PR, Brasil. / Universidade Federal do Paraná. Complexo Hospital de Clínicas. Curitiba, PR, Brasil. / Instituto Nacional de Ciência e Tecnologia para Medicina Regenerativa. Rio de Janeiro, RJ, Brasil. |
| publishDate |
2021 |
| dc.date.accessioned.fl_str_mv |
2021-06-17T17:21:54Z |
| dc.date.available.fl_str_mv |
2021-06-17T17:21:54Z |
| dc.date.issued.fl_str_mv |
2021 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
SENEGAGLIA, Alexandra Cristina et al. Combined use of Tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case Report. Cell Transplantation, v. 30, p. 1–10, 2021. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/47750 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1555-3892 |
| dc.identifier.doi.none.fl_str_mv |
10.1177/09636897211021008 |
| identifier_str_mv |
SENEGAGLIA, Alexandra Cristina et al. Combined use of Tocilizumab and mesenchymal stromal cells in the treatment of severe Covid-19: Case Report. Cell Transplantation, v. 30, p. 1–10, 2021. 1555-3892 10.1177/09636897211021008 |
| url |
https://www.arca.fiocruz.br/handle/icict/47750 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
SAGE Publications |
| publisher.none.fl_str_mv |
SAGE Publications |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/47750/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/47750/2/09636897211021008ok.pdf https://www.arca.fiocruz.br/bitstream/icict/47750/3/09636897211021008ok.pdf.txt |
| bitstream.checksum.fl_str_mv |
783568c2893d2e25a99990b126be1772 5fa4f533aef0f0f2f1c54c4d55bf4a70 7a4983e7ec443c846b4c1d91c7ee87ce |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813008996963975168 |